Activation of B lymphocytes with human serum-treated zymosan.
C3 fragments fixed on zymosan particles were presented to resting human B lymphocytes. The opsonized zymosan (Ops-Z) particles induced release of leukocyte migration inhibitory factor, a slight decrease in mIgD, and a slight increase in the activation marker Blast-2. The B cells did not proceed further along the pathway of activation: they did not respond to B cell growth factor (BCGF) and Ops-Z did not synergize with other activators for BCGF response either. Thus, we found that interaction between C3 fragments and CR2 initiates the activation of human B lymphocytes, but this is limited to the early phase.
D000954:Antigens, Surface / Q000378:metabolism; D001402:B-Lymphocytes / Q000166:cytology*; D003176:Complement C3 / Q000502:physiology*; D004247:DNA / Q000096:biosynthesis; D006801:Humans; D066298:In Vitro Techniques; D015847:Interleukin-4; D007378:Interleukins / Q000494:pharmacology; D007961:Leukocyte Migration-Inhibitory Factors / Q000096:biosynthesis; D008213:Lymphocyte Activation; D011951:Receptors, Complement / Q000378:metabolism; D015054:Zymosan / Q000494:pharmacology*
D000954:Antigens, Surface; D003176:Complement C3; D007378:Interleukins; D007961:Leukocyte Migration-Inhibitory Factors; D011951:Receptors, Complement; D015847:Interleukin-4; D004247:DNA; D015054:Zymosan